Literature DB >> 1657666

Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats.

C Orskov1, S S Poulsen.   

Abstract

We demonstrated specific binding of the insulin-releasing hormone glucagonlike peptide (GLP)-I-(7-36)-amide, an intestinal product of proglucagon, to pancreatic islet cells by autoradiography using 125I-labeled GLP-I-(7-36)-amide incubated with tissue specimens of extracerebral rat organs. We also found binding of 125I-GLP-I to insulin-, glucagon-, and somatostatin-immunoreactive cells by combined autoradiographic and immunohistochemical analysis of pancreatic specimens using antisera against insulin, glucagon, and somatostatin. An accumulation of radioactivity was also observed in the stomach surface epithelium but could not be prevented by excess unlabeled peptide. No binding was found in other tissues investigated, including the lungs and the small intestinal mucosa. Localization of the binding sites identifies the pancreatic islets as the prime target for GLP-I-(7-36)-amide and suggests that it exerts direct effects on islet cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657666     DOI: 10.2337/diab.40.10.1292

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  15 in total

Review 1.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 2.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models.

Authors:  Janne Lehtonen; Lauge Schäffer; Morten Grønbech Rasch; Jacob Hecksher-Sørensen; Jonas Ahnfelt-Rønne
Journal:  Islets       Date:  2015       Impact factor: 2.694

4.  Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations.

Authors:  K A Gronau; P L Brubaker
Journal:  Endocrine       Date:  1995-11       Impact factor: 3.633

Review 5.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 7.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

8.  Expression of the GLP-1 receptor in mouse, rat, and human pancreas.

Authors:  Ditte Tornehave; Peter Kristensen; John Rømer; Lotte Bjerre Knudsen; R Scott Heller
Journal:  J Histochem Cytochem       Date:  2008-06-09       Impact factor: 2.479

9.  Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans.

Authors:  Eric M Snyder; Richard D Carr; Carolyn F Deacon; Bruce D Johnson
Journal:  Appl Physiol Nutr Metab       Date:  2008-10       Impact factor: 2.665

Review 10.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.